Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Amphastar Pharmaceuticals, Inc. amended Manufacturing Amendment with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. valued at Change in value not determinable; expands territory globally except US and Canada for Lidocaine and (effective 2026-01-06).
- Action
- amendment
- Agreement
- supply
- Counterparty
- Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
- Value
- Change in value not determinable; expands territory globally except US and Canada for Lidocaine and
- Effective
- 2026-01-06
Exact text from the filing
On January 6, 2026, Amphastar Nanjing Pharmaceuticals, Inc., the Chinese subsidiary of Amphastar and Hanxin entered into an amendment to the Manufacturing Agreement (the “Manufacturing Amendment”), originally entered into on April 19, 2022, as previously reported by the Company on a Current Report on Form 8-K filed on April 22, 2022.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Amphastar Pharmaceuticals, Inc. entered into License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. valued at Amphastar made an upfront payment of $2 million; development milestone payments up to $14 million; s (effective 2026-01-06).
- Action
- entry
- Agreement
- license
- Counterparty
- Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
- Value
- Amphastar made an upfront payment of $2 million; development milestone payments up to $14 million; s
- Effective
- 2026-01-06
Exact text from the filing
On January 6, 2026, Amphastar Pharmaceuticals, Inc (“Amphastar” or, the “Company”), and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (“Hanxin”), entered into a License Agreement (“License Agreement”) pursuant to which Hanxin is granting an exclusive license to certain intellectual property controlled by Hanxin to develop, make, use and commercialize products incorporating or comprising of corticotropin compound (“Licensed Product”) in the United States and Canada (the “Territory”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Amphastar Pharmaceuticals, Inc. amended Distribution Amendment with Hong Kong Genreach Limited valued at Change in value not determinable; expands region with additions of Middle East and Southeast Asian c (effective 2026-01-06).
- Action
- amendment
- Agreement
- supply
- Counterparty
- Hong Kong Genreach Limited
- Value
- Change in value not determinable; expands region with additions of Middle East and Southeast Asian c
- Effective
- 2026-01-06
Exact text from the filing
On January 6, 2026, Armstrong Pharmaceuticals, Inc. a wholly-owned subsidiary of the Amphastar and Hong Kong Genreach Limited (“Genreach”) a wholly-owned subsidiary of Hanxin entered into an amendment to the Distribution Agreement (the “Distribution Amendment”), originally entered into on August 28, 2024, as previously reported by the Company on a Current Report on Form 8-K filed on August 30, 2024 (the “Distribution Agreement”).
View on SEC.gov